Zuyang Yuan

Zuyang Yuan

Auto-generated profile, based on publicly available information

Zuyang Yuan

Chinese Academy of Medical Sciences and Peking Union Medical College

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2020 in Cancer Communications
Verified
Journal Article
Open access
PDF file
ZYZuyang Yuan
Zuyang Yuan
XWXinfeng Wang
Xinfeng Wang
XGXiao Geng
Xiao Geng
YLYin Li
Yin Li
JMJuwei Mu
Juwei Mu
JHJie He
Jie He
Esophageal cancer (EC) is a common cancer and is histopathologically classified into esophageal squamous cell carcinoma and esophageal adenocarcinoma. EC is a worldwide public health issue because of late diagnosis and lack of effective therapy. In contrast to standard tumor biopsies, liquid biopsies are emerging as a tool which is minimally invasive that can complement or even substitute more classical approaches. Specifically, cell‐free DNA (cfDNA) has shown promise in cancer‐related clinical applications. Indeed, cfDNA has been shown to be an effective circulating biomarker for non‐invasive cancer diagnosis and monitoring of cancer patients. Although the clinical application of cfDNA has been reported on other cancers, few studies have evaluated its use in EC. Here, we review this relevant literature and discuss limitations and advantages of its application in the diagnosis and monitoring of EC.

15 May 2017 in Chinese Journal of Cancer
Verified
Journal Article
Open access
PDF file
ZYZu-Yang Yuan
Zu-Yang Yuan
SGShugeng Gao
Shugeng Gao
JMJu-Wei Mu
Ju-Wei Mu
QXQi Xue
Qi Xue
YMYousheng Mao
Yousheng Mao
JHJie He
Jie He
Thymoma is an uncommon tumor without a widely accepted standard care to date. We aimed to investigate the clinicopathologic variables of patients with thymoma and identify possible predictors of survival and recurrence after initial resection. We retrospectively selected 307 patients with thymoma who underwent complete resection at the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China) between January 2003 and December 2014. The associations of patients’ clinical characteristics with prognosis were estimated using Cox regression and Kaplan–Meier survival analyses. During follow-up (median, 86 months; range, 24–160 months), the 5- and 10-year disease-free survival (DFS) rates were 84.0% and 73.0%, respectively, and the 5- and 10-year overall survival (OS) rates were 91.0% and 74.0%, respectively. Masaoka stage (P < 0.001), World Health Organization (WHO) histological classification (P < 0.001), and postoperative radiotherapy after initial resection (P = 0.006) were associated with recurrence (52/307, 16.9%). Multivariate analysis revealed that, after initial resection, WHO histological classification and Masaoka stage were independent predictors of DFS and OS. The pleura (25/52, 48.0%) were the most common site of recurrence, and locoregional recurrence (41/52, 79.0%) was the most common recurrence pattern. The recurrence pattern was an independent predictor of post-recurrence survival. Patients with recurrent thymoma who underwent repeated resection had increased post-recurrence survival rates compared with those who underwent therapies other than surgery (P = 0.017). Masaoka stage and WHO histological classification were independent prognostic factors of thymoma after initial complete resection. The recurrence pattern was an independent predictor of post-recurrence survival. Locoregional recurrence and repeated resection of the recurrent tumor were associated with favorable prognosis.

20 February 2014 in Chinese Medical Journal
Verified
Journal Article
Open access
JMJuwei Mu
Juwei Mu
ZYZuyang Yuan
Zuyang Yuan
BZBaihua Zhang
Baihua Zhang
LNLi Ning
Li Ning
FLfang lyu
fang lyu
JHJie He
Jie He
Background: In order to minimize the injury reaction during the surgery and reduce the morbidity rate, hence reducing the mortality rate of esophagectomy, minimally invasive esophagectomy (MIE) was introduced. The aim of this study was to compare the postoperative outcomes in patients with esophageal squamous cell carcinoma undergoing minimally invasive or open esophagectomy (OE). Methods: The medical records of 176 consecutive patients, who underwent minimally invasive esophagectomy (MIE) between January 2009 and August 2013 in Cancer Institute & Hospital, Chinese Academy of Medical Sciences, were retrospectively reviewed. In the same period, 142 patients who underwent OE, either Ivor Lewis or McKeown approach, were selected randomly as controls. The clinical variables of paired groups were compared, including age, sex, Charlson score, tumor location, duration of surgery, number of harvested lymph nodes, morbidity rate, the rate of leak, pulmonary morbidity rate, mortality rate, and hospital length of stay (LOS). Results: The number of harvested lymph nodes was not significantly different between MIE group and OE group (median 20 vs. 16, P=0.740). However, patients who underwent MIE had longer operation time than the OE group (375 vs. 300 minutes, P <0.001). Overall morbidity, pulmonary morbidity, the rate of leak, in-hospital death, and hospital LOS were not significantly different between MIE and OE groups. Morbidities including anastomotic leak and pulmonary morbidity, in-hospital death, hospital LOS, and hospital expenses were not significantly different between MIE and OE groups as well. Conclusions: MIE and OE appear equivalent with regard to early oncological outcomes. There is a trend that hospital LOS and hospital expenses are reduced in the MIE group than the OE group.

1 June 2014
Verified
Journal Article
Open access
PDF file
ZYZu-Yang Yuan
Zu-Yang Yuan
GCGui-Yu Cheng
Gui-Yu Cheng
KSKelin Sun
Kelin Sun
YMYousheng Mao
Yousheng Mao
JLJian Li
Jian Li
JMJu-Wei Mu
Ju-Wei Mu
Comparative study of video-assisted thoracic surgery versus open thymectomy for thymoma in one single center

13 May 2010 in Gene Therapy
Verified
Journal Article
Open access
PDF file
CXC Xin
C Xin
SYS Ye
S Ye
YMY Ming
Y Ming
ZSZ Shenghua
Z Shenghua
MQM Qingfang
M Qingfang
ZYZ Yongsu
Z Yongsu
Lidamycin (LDM) is a new member of enediyne antitumor antibiotics family that can be separated and reconstituted. It consists of a labile active enediyne chromophore (AE) and a noncovalently bound apoprotein (LDP). LDM is now in phase II clinical trials. In this study, we described the antitumor features of a fusion protein of LDM, anti-CD20Fab-LDM, targeted to CD20 expressed by B-lymphoid malignancies. Especially, LDM was prepared by a novel two-step method including DNA recombination and molecular reconstitution. Anti-CD20Fab-LDM exerted potent cytotoxicity against CD20+ B-cell lymphoma cell lines in vitro (IC50: 10–30 pM) and in the Raji xenograft model. Two Raji xenografts were allowed to grow to an initial mass of 80 and 500 mm3, respectively, and then anti-CD20Fab-LDM was administered intravenously with the highest dose of 4 nmol kg−1. The inhibition rates of tumor growth were 90.1 and 85%, which were saliently superior to those of nontargeted LDM. It is noteworthy that anti-CD20Fab-LDM can inhibit the growth of patient-derived cells, including rituximab-resistant patient-derived cells. Thus, CD20-targeted delivery of LDM is a specific and potent therapeutic strategy for B-lymphoid malignancies. In addition, the two-step approach could serve as a new technology platform for making a series of highly potent engineered antibody-based drugs.